相关实验视频
Updated: Jul 12, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
385
在癌细胞上的新兴免疫检查点分子:CD24和CD200
Sun Young Moon1, Minjoo Han1, Gyoungah Ryu1
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of Korea.
International journal of molecular sciences
|October 28, 2023
概括
新的癌症免疫治疗点CD24和CD200显示出有前途. 这些免疫检查点分子在许多癌症中过度表达,为增强抗瘤反应和改善患者治疗结果提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 目前的癌症免疫疗法依赖于自适应性免疫检查点,在持续的患者反应方面取得的成功有限.
- 瘤微环境具有由过度表达的免疫检查点分子抑制的髓状细胞,呈现出新的治疗点.
研究的目的:
- 审查了解CD24和CD200作为癌症免疫检查点分子的最新进展.
- 探索针对癌症治疗的CD24和CD200的治疗潜力.
主要方法:
- 关于CD24,CD200及其受体 (Siglec-10,CD200受体) 的最近研究的文献综述.
- 分析这些分子在瘤免疫逃避和髓状细胞抑制中的作用.
主要成果:
- CD24和CD200在各种癌症类型中经常过度表达,有助于免疫逃避.
- 这些分子与髓状细胞上的Siglec-10和CD200受体接触,作为关键信号检查点.
结论:
- CD24和CD200代表重要的新兴免疫检查点,具有相当大的治疗潜力.
- 向CD24和CD200为开发新型抗癌免疫疗法提供了一个有希望的途径.
关键词:
CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD200 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD3 CD2 CD4 CD2 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD3 CD2 CD2 CD2 CD2 CD2 is included included included included included included这是一个CD200受体.CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24 CD24西格莱克-10号飞机.免疫检查点分子免疫检查点分子相关概念视频
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
T Cell Activation and Clonal Selection
764
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
764
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Immunoglobulin-like Cell Adhesion Molecules
3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K

